BridgeBio Pharma, Inc. (BBIO)

28,73 +1,03 (+3,72 %) À la clôture : 04:00PM EDT

BridgeBio Pharma, Inc.

3160 Porter Drive
Suite 250
Palo Alto, CA 94304
United States
650 391 9740
https://bridgebio.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 550

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Neil Kumar Ph.D.	Co-Founder, President, CEO & Director	1,53M	S.O.	1979
Dr. Charles J. Homcy M.D.	Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director	563,2k	S.O.	1948
Dr. Frank P. McCormick Ph.D.	Co-Founder, Chairman of Oncology & Director	542,78k	S.O.	1950
Dr. Brian C. Stephenson C.F.A., Ph.D.	CFO & Secretary	1,15M	S.O.	1981
Dr. Richard H. Scheller Ph.D.	Chairman of Research & Development	509,62k	S.O.	1953
Dr. Uma Sinha Ph.D.	Chief Scientific Officer	1,31M	S.O.	1958
Grace Rauh	Vice President of Communications	S.O.	S.O.	S.O.
Mr. Eli M. Wallace Ph.D.	Chief Scientific Officer of Oncology	S.O.	S.O.	1967
Dr. Thomas Trimarchi Ph.D.	Chief Product Officer	S.O.	S.O.	S.O.
Dr. Eric Michael David J.D., M.D., Ph.D.	Chief Executive Officer of Gene Therapy	S.O.	S.O.	1972

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de BridgeBio Pharma, Inc. en date du 1 mai 2024 est 10. Les scores principaux sont Audit : 3; Société : 10; Droits des actionnaires : 8; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.